Latest Pharma and Biotech News
Pharmaceutical
27 November 2024 The strain of opioid use disorder (OUD), a chronic neurological disorder characterized by the compulsive, repeated use of opioid drugs, has weighed heavily on many countries in recent years, especially the USA.
Today's issue
Refine Search
Biotechnology
US tumor drug resistance specialist Deciphera Pharmaceuticals today announced that the Australian Therapeutics Goods Administration (TGA) has approved Qinlock (ripretinib) for the treatment of adult patients with advanced gastrointestinal stromal tumor (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. 14 July 2020
Biotechnology
Terms for a research project focusing on targeted and immuno-oncology therapies have been agreed by French pharma major Sanofi and the MD Anderson Cancer Center. 14 July 2020
Biotechnology
US precision cancer therapy specialist Blueprint Medicines has entered into a global collaboration with Swiss giant Roche and its subsidiary Genentech, worth a potential $1.7 billion. 14 July 2020
Biotechnology
Privately-held Dewpoint Therapeutics has announced an exclusive collaboration with Merck & Co, the US pharma giant known as MSD outside the USA and Canada. 14 July 2020
Biotechnology
Washington, USA-based biotech has received a Refusal to File letter for leronlimab, causing shares in the company to fall more than a fifth. 14 July 2020
Biotechnology
US pharma giant Pfizer has announced the registration of Bisponsa (inotuzumab ozogamycin), which is an innovative drug, designed for the treatment of acute lymphoblastic leukemia (ALL), in Russia. 14 July 2020
Biotechnology
Nasdaq on Monday announced that US RNA therapeutics and vaccine specialist Moderna Therapeutics will become a component of the Nasdaq-100 Index, prior to market open on Monday, July 20, 2020 14 July 2020
Biotechnology
Anglo-Swedish drugmaker AstraZeneca has announced that the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for Brilinta (ticagrelor) for the reduction of subsequent stroke in patients who experienced an acute ischemic stroke or transient ischemic attack (TIA). 13 July 2020
Biotechnology
Roche has added to the body of evidence supporting Hemlibra (emicizumab) in hemophilia A. 13 July 2020
Biotechnology
The US Food and Drug Administration (FDA) has granted Fast Track designation to two vaccine candidates from the Pfizer and BioNTech BNT162 mRNA-based vaccine program. 13 July 2020
Biotechnology
Swiss pharma giant Roche has issued a disappointing update on the Phase III IMagyn050 study. 13 July 2020
Biotechnology
US RNAi therapy specialist Alnylam Pharmaceuticals says that the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has granted lumasiran, an investigational RNAi therapeutic in development for the treatment of primary hyperoxaluria type 1 (PH1), a positive scientific opinion through the Early Access to Medicines Scheme (EAMS). 13 July 2020
Biotechnology
US biotech Ovid Therapeutics and family-owned Italian drugmaker Angelini Pharma have entered into a partnership to manufacture and commercialize the former’s OV101 in Europe. 13 July 2020
Biotechnology
Biocon has received the Drugs Controller General of India’s (DCGI) approval to market Alzumab (itolizumab) injection 25mg/5mL solution for emergency use in India for the treatment of cytokine release syndrome (CRS) in moderate to severe ARDS (acute respiratory distress syndrome) patients due to COVID-19. 13 July 2020
Biotechnology
Investment giant Blackstone has announced the final close of its fund in life sciences. 10 July 2020
Biotechnology
Swedish firm Hansa Biopharma is 1.1 billion Swedish kronor ($121 million) better off after completing a share placement. 10 July 2020
Biotechnology
Swiss pharma giant Novartis has noted the publication of full results from the Phase III IRIDIUM study in The Lancet Respiratory Medicine, reminding physicians of the data supporting Enerzair Breezhaler (indacaterol acetate, glycopyrronium bromide and mometasone furoate) in uncontrolled asthma. 10 July 2020
Biotechnology
GlobalData expects the Hodgkin’s lymphoma market to grow from $1.2 billion in 2019 to $2.1 billion in 2029 across the eight major markets (8MM) at a moderate compound annual growth rate (CAGR) of 5.5%. 9 July 2020
Biotechnology
Spanish company Grifols has begun European delivery of Tavlesse (fostamatinib) to treat chronic immune thrombocytopenia (ITP) in adult patients refractory to other treatments. 9 July 2020
Biotechnology
US biotech Kymera Therapeutics has entered into a multi-program strategic collaboration with Sanofi to develop and commercialize first-in-class protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases. 9 July 2020
All news
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeOne Medicines, formerly BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze